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Retrospective Study

Treatment of Metastatic Spinal Lesions with a
Navigational Bipolar Radiofrequency Ablation
Device: A Multicenter Retrospective Study
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Background: Spinal metastatic lesions are a common occurrence among oncology patients
and contribute to significant morbidity. Treatment options have been limited in their effectiveness
and scope to this point.
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Method: One hundred twenty-eight metastatic lesions were identified in 92 patients who
underwent a total of 96 procedures. Cement augmentation was performed when the vertebral
body was at risk or had a pathological fracture. Visual analogue scale (VAS) scores were obtained
preoperatively as well as postoperatively at the one week, one month, and 6 month time points.
Interval change in the patients’ pain medications was recorded. Postoperative imaging was used
to assess tumor burden at the treated level when available.
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Objective: This study aims to report the safety and efficacy of radiofrequency ablation (RFA)
of malignant spinal lesions using a novel RFA bipolar tumor ablation system which includes a
navigational electrode containing 2 active thermocouples.
Study Design: IRB approved multicenter retrospective review of patients receiving RFA as a
treatment of metastatic osseous lesions between March 2012 and March 2013.
Setting: This study consists of patients from 5 large academic centers.

Results: RFA was technically successful in all of the lesions without complication or thermal
injury. Our study demonstrated significant (P < 0.01) decreases in the VAS scores at one
week, one month, and 6 months postoperatively. In our largest center, 54% of our patients
experienced a decrease and 30% had no change in their pain medications postoperatively. Sixtytwo percent of the spinal lesions in this largest institution were located in the posterior vertebral
body. Post-ablation imaging confirmed size of ablation zones consistent with that measured by
the thermocouples.
Limitations: The main limitations of this study are the heterogeneous patient population,
data set, and potential confounding variable of concurrent cement augmentation.
Conclusion: The STAR System is an RFA device that was safely and effectively used in the
treatment of spine metastatic osseous lesions. This new device allows RFA treatment of previously
untreatable lesions with resultant reduction in pain that was not controlled by systemic or
radiation therapy.
Key words: Radiofrquency ablation, pain, osseous metastasis, spine, interventional oncology,
oncology, pain management, tumor, vertebral augmentation
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sseous metastatic lesions are common and
have been seen in up to 80% of patients with
cancer at the time of death (1), with spinal
metastasis seen in approximately 50% of these patients
(2). The predilection for growth of tumor cells within
the bone microenvironment was recognized as far back
as 1889 by Paget and has been termed the “seed and
soil” hypothesis (3). While the pathogenesis remains
unclear, bone metastasis remains the most prevalent
cause of chronic pain within cancer patients (4).
The most frequent site of bone metastasis is the
vertebrae, likely related to the high hematopoietic
activity and vascularization of the spine (5). Management of these patients is challenging and traditionally
involves a combination of radiation and chemotherapy
in adjunct with analgesics. Surgery has remained a
mainstay of treatment in patients with neurologic deficit, instability requiring stabilization, or with a longer
life expectancy.
Surgical options in these patients with decreased
life expectancy are often morbid and present a therapeutic dilemma. Minimally invasive procedures, including thermal ablation, are safe and effective treatments
of painful osseous metastatic lesions in patients who
are not surgical candidates or choose not to undergo
surgery (6). Radiofrequency ablation (RFA) has been
well established for the treatment of metastases to the
liver and kidneys (7-9), and within the past few years has
been increasingly utilized in management of osseous
metastases. In the spine, this treatment has traditionally been limited to lesions within the anterior vertebral
body since this location is more accessible and further
away from sensitive neural elements (10). Plasma mediated RFA, the most reported method of tumor ablation
within the spine, employs radiofrequency energy to
excite electrolytes and create a plasma field that results
in the disruption of molecular bonds at relatively low
temperatures (40 to 70 degrees Celsius) (11,12). However, the resultant thermal profile and ablation zone
cannot be monitored and are unpredictable, posing a
potential risk of injury to nearby neural elements.
RFA uses thermal energy to destroy tissue surrounding an electrode, resulting in coagulative necrosis of tissue from high temperatures. Optimal tissue destruction
occurs between 50 – 90°C (13). The radius of the ablation zone is dependent on the tissue temperature and
time the tissue is maintained at that temperature. Accurate temperature measurements are critical to ensure
proper tumor kill and also minimize unintended tissue
destruction. In the short term, thermal destruction of
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pain sensitive nerve fibers ceases transmission of pain
signals. Tumor cell necrosis has also been implicated in
decreasing the cytokine mediated pain pathways involving interleukins and tumor necrosis factor. RFA also
delays tumor progression to the sensitive periosteum
(14,15). The combination of these mechanisms leads
to rapid decrease in pain that can provide long-lasting
relief.
The purpose of this multicenter retrospective study
was to determine the safety and efficacy of RFA using
an articulating tumor ablation system that permits
navigation within bone and real time monitoring of the
peripheral edge of the ablation zone in spinal metastatic lesions. Additionally, vertebral augmentation was
delivered via the same guiding cannula if there was already a pathological fracture, concern for fracture due
to a large destructive lesion, or for potential structural
instability.

Methods
Patient Data
This retrospective analysis involved 5 institutions
and included patients who received RFA as a treatment
of osseous metastatic disease using the STAR tumor
ablation system between March 2012 and March 2013.
One hundred and twenty-eight osseous spine metastatic lesions were treated in 92 patients with or without concurrent vertebral augmentation. Two of these
patients had a second RFA procedure at the same site
of disease and 2 patients had a second RFA procedure
for metastasis at a different site leading to a total of
96 procedures. All patients who underwent RFA with
the STAR system in these 5 centers were included in the
study. This retrospective analysis was approved by the
Institutional Review Board.
The most common type of primary tumor was lung
cancer (27%), followed by breast cancer (16%), and sarcoma (9%). Procedural outcomes including complications and pain relief were examined at each institution.
All 5 institutions obtained visual analogue scale (VAS)
scores on patients preoperatively and one month postoperatively. In addition to these time points, one institution obtained VAS scores one week postoperatively,
and one institution obtained scores both one week and
6 months postoperatively. Table 1 summarizes the VAS
scores obtained from all 5 centers.
More detailed data was available from the center
which performed the largest number of cases, accounting for 34 of the 92 patients or 70 of the 128 treated
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lesions (55%). This institution also included more detailed demographic and procedural data such as lesion
location, ablation time, number of zones, and ablation
temperatures, as well as post-procedural imaging when
available. Table 2 summarizes the VAS scores obtained
from this center.
Within this larger institution, 13 of the 34 patients
(38%) were male and 21 (62%) were female. The population within this center ranged in age from 35 to 84
years old, and had a mean age of 60 years. Evidence of
prior radiation was found in the records of 17 patients
(43%) and prior chemotherapy in 24 patients (60%) as
part of their treatment prior to ablation. Of the 70 spine
lesions, half of these lesions were within the thoracic
spine, 39% within the lumbar spine, and 11% within
the sacrum. Additionally, vertebral augmentation was
performed in 66 of the 70 (94%) spinal lesions to provide stabilization post-ablation or for pathological fracture. This demographic and augmentation data was not
available for the other 4 institutions.

Procedure
Prior to the procedure, written informed consent
was obtained after a detailed explanation of the
therapy benefits, treatment alternatives, and complications. Pre-procedural planning was performed using
cross-sectional imaging to determine pedicle access and
the number of targeted ablations based on lesion location, size, and pre-clinical thermal distribution curves
for the device. Magnetic resonance imaging (MRI) was

preferred due to better evaluation of posterior tumor
extension and canal or neuroforaminal involvement.
Ninety-four of the procedures were performed
under conscious sedation. The remaining 2 procedures
were performed under general anesthesia due to
intractable pain and inability to achieve pain control
under conscious sedation. The preferred method of
treatment is conscious sedation to enable monitoring
of neurologic symptoms. Fluoroscopy or computed tomography (CT) was utilized for image guidance based
on lesion characteristics and operator preference for
safety reasons. Full sterile technique was used during
the procedure including cap, mask, hand hygiene,
sterile gloves, and sterile drape. RFA was performed
with the STAR Tumor Ablation System (comprised of
the SpineSTAR ablation instrument and the MetaSTAR
generator, DFINE, San Jose, CA). The SpineSTAR is an
articulating, navigational and bipolar radiofrequency
electrode containing a pair of thermocouples positioned along the length of the electrode, 10 and 15
mm from the center of the ablation zone. There is a
3:2 length to width aspect ratio ablation zone with
the maximum ablation zone of 3 cm by 2 cm when the
proximal thermocouple reaches 50 degrees Celsius. The
MetaSTAR generator continuously displays the 2 thermocouple readings permitting real time monitoring of
the peripheral edge of the ablation zone (Fig. 1).
All vertebral lesions were targeted from a transpedicular/parapedicular approach using the provided
10-gauge co-axial working cannula. The working can-

Table 1. Visual Analogue Scale (VAS) Scores at all centers.

Average

Standard
Deviation

Pre-procedural

7.51

2.46

1 week

1.73

2.28

1 month

2.25

2.44

6 months

1.75

2.62

Median

Number (n)

8.00

92

< 0.0001

1.00

56

< 0.0001

1.25

83

0.009

0.00

9

P Value1

Based on matched two-tailed Student t test.

1

Table 2. Visual Analogue Scale (VAS) Scores at our largest institution.

Average

Standard Deviation

7.35

2.90

Pre-procedural

P Value1

Median

Number (n)

8.00

34

1 week

2.47

2.42

< 0.0001

2.00

32

1 month

2.80

2.73

< 0.0001

2.25

29

6 months

1.75

2.62

0.009

0.00

9

Based on matched two-tailed Student t test.

1
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Fig. 1. STAR (Spinal Tumor Ablation with Radiofrequency) System Components: A. SpineSTAR Instrument, 10 gauge,
articulated, extendable bipolar electrode. B. Distal end of SpineSTAR containing 2 thermocouples (red dots), located at 10
and 15 mm from center of ablation zone which permit real-time monitoring of proximal peripheral edge of ablation zone. C.
MetaSTAR Generator Display: proprietary RF generator with impedance and temperature controlled algorithm.
nula was advanced into the portion of the vertebral
body necessary for access to the lesion, and then the articulating midline osteotome was used to make desired
channels prior to ablation. The SpineSTAR electrode
was then deployed to the desired location.
A variable number of ablation zones, temperatures, and ablation times were utilized based on size,
shape, and location of lesion. These variables were
recorded for each procedure. In cases in which there
was concern for adjacent neural damage, special neural
thermal protection techniques, described by Buy et al
(16), involving epidural or neuroforaminal thermocouples and injection of CO2 or cooled 5% dextrose water
were used. Following ablation, cement augmentation
(StabiliT Vertebral Augmentation System, DFINE Inc,
San Jose, CA) was performed in cases where there was
a pathologic fracture or vertebral instability was of
concern due to a large destructive lesion via the same
working cannula.

Results
RFA was technically successful in all of the 128 osseous metastatic lesions treated without complications or
thermal injury. The VAS scores obtained from all centers
as well as our largest center are summarized in Tables
1 and 2, respectively. The postoperative VAS scores at
the one week, one month, and 6-month time points
were statistically significant using a paired two-tailed
Student t test.
In the largest center, which comprised 34 of the
92 treated patients, detailed procedural information
was obtained. The ablation time at each treated lesion ranged from 55 to 653 seconds, with an average
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ablation time of 361 seconds. Each lesion was treated
with an average of 4.3 overlapping ablation zones.
The average temperature recorded at the proximal
thermocouple on the electrode (representing the temperature reading at the most peripheral aspect of the
ablation zone) was 50 degrees Celsius and the average
temperature recorded at the distal thermocouple was
73 degrees Celsius. Twenty-one (62%) of the 34 patients
had treatment of lesions located in the posterior vertebral body (Fig. 2).
In addition, within this largest institution, change
in pain medication usage after the ablation was compared to the preoperative information at this institution. A decrease in pain medications was seen in 54%
of patients after treatment, with 30% reporting no
change in medication usage, and 16% saying their pain
regimen had increased.
Cement augmentation was successfully performed
in 92 of the 96 treated lesions through the same working cannula used for the RFA. Adequate fill was seen in
all cases. Cement extravasation was noted in 2 patients,
one into a draining vein and one into a sacral neural
foramen. Both extravasations were asymptomatic. Two
of the 4 patients not receiving vertebral augmentation
went on to fracture and subsequently had cement augmentation at 3 months and one year.
Some patients underwent post-procedural MRI
which demonstrated discrete ablation zones with a
length to width aspect ratio of 3:2 consistent in size
with that expected based on the temperatures obtained by the thermocouplers during the ablation (Fig.
3). Thirteen of the 34 patients at the largest center had
follow-up postoperative imaging, 10 of which demon-
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A

B
Fig. 2. 45-year-old woman with metastatic breast cancer who has multiple metastases including a posterior vertebral body lesion
at T11. Axial bone windowed CT image (A) with T11 lytic lesion involving the posterior wall and right pedicle (white arrow).
Axial T1 weighted (T1W) post contrast MRI image (B) 4 days post-procedure demonstrating the ablation zone (white arrows)
extending to the posterior vertebral body cortex and into the right pedicle.

Fig. 3. 52-year-old woman with retroperitoneal leiomyosarcoma metastatic to the posterior L4 vertebral body.
Prone axial bone windowed CT image (A) demonstrating the STAR device placed from a right pedicle approach during ablation.
The STAR device is located just anterior to the lytic lesion (*). Axial T1 weighted post contrast MRI image (B) demonstrates
the ablation zone length being one and a half times the width, as indicated by the 3 length : 2 width aspect ratio (white arrows)
obtained with the STAR device.

www.painphysicianjournal.com
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strated stable or improved metastatic disease at the
level of treatment after an average of 92 days. Three
patients demonstrated progression at the treated level
after an average of 82 days. Two of these patients underwent a second RFA with the STAR ablation system
at the same levels. The third patient demonstrated
diffusely increased metastatic progression after just 16
days and underwent systemic treatment.

Discussion
Bone is the most common site of metastatic disease
after lung and liver (17) and one of the most common
causes of chronic pain among cancer patients (18). Approximately two-thirds of cancer patients will develop
bone metastases and it is estimated that over 10% of
patients with cancer will develop symptomatic spinal
metastases (19). More than 50% of patients with spinal
metastases have multiple levels involved (20); because
of this, treating osseous metastatic disease, particularly
within the spine, is an important aspect of therapy and
palliation among patients with advanced malignancy
(21,22). Many patients have a minimal or only brief response to traditional therapies and onset of pain relief
can take months (23). Additionally, invasive surgical
procedures are usually not warranted in these patient
populations due to short expected lifespan and comorbidities. RFA with or without cement augmentation
does not hinder or delay the use of adjuvant therapies
(24).
The first reported use of RFA in bone was in the
treatment of osteoid osteoma by Rosenthal et al in
1992 (25), and since then has been used for treatment
of osseous metastatic disease (10,26-29). The procedure’s rapid onset of pain relief and low rates of morbidity make it an optimal technique in managing these
lesions.
In a multicenter trial of 62 patients, Goetz et al
noted pain relief in nearly 80% of patients treated with
RFA (26). Callstrom et al demonstrated RFA to be an
effective treatment of metastatic pain in approximately
83% of patients who failed chemoradiation therapy
(26,27). Thanos et al also found RFA to provide significant pain relief in patients who failed standard treatment with pain relief achieved between 4 days and one
week after therapy in 90% – 100% of patients (27,28).
In the largest center of this study, 43% of patients were
documented to have failed radiation while 60% failed
chemotherapy as their pre-ablation treatment. The
actual number of patients who failed these treatments
is likely even higher as there was incomplete documen-
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tation of these results within the oncology medical
records. In all of these referenced cohorts and trials,
spine lesions were actually a small percentage of the
total lesions treated.
The use of RFA in the spine has traditionally been
limited to the anterior vertebral body due to the close
proximity of tumor to neural tissues and limited treatment angle derived from the trans- or extra-pedicular
approach of conventional RFA systems (28). Over half
of the lesions treated in our largest center were located
in the posterior vertebral body, lesions that were previously thought to be untreatable with RFA. Treatment
of lesions located more posteriorly or with posterior
cortical bone destruction was contraindicated due to
the close relationship of the spinal cord and nerve roots
(29). The posterior wall lesions were easily accessed
with the SpineSTAR articulating electrode which also
provided the operator with the additional advantage
of real time monitoring of the temperature at the peripheral edge of the ablation zone (Fig. 4).
The addition of cement posteriorly maintains a
theoretical risk of spinal canal compromise, and should
be done in experienced hands with caution. The posterior column is the strongest portion of the spine due
to the large cortical margins and supporting posterior
elements (30). The decreased necessity of adding cement to strengthen the column is a benefit. Therefore
the STAR ablation system has the ability to treat these
lesions which were previously deemed unsafe.
The ability to create multiple ablation zones
through the same introducer needle using the navigational electrode resulted in an average of 4.3 ablation
zones within each metastatic osseous lesion treated in
this study allowing for more complete tumor ablation
(Fig. 4).
In this study, statistically significant pain relief was
seen among patients at the one week, one month,
and 6 month post ablation time points. Many studies
have reported significant and enduring reduction in
pain control of bony metastasis with improvement in
overall quality of life after RFA (26-29,31). Long-term
pain relief has been reported as far out as one year in
many cases (28,31). Additionally, treatment with RFA
has been shown to decrease the use of analgesic medications postoperatively (26-28). Hoffman et al saw this
decline in 70% of their treated patients (4). A decrease
in pain medication was seen in 54% of the patients in
this cohort.
Ninety-six percent of patients received vertebral
augmentation following the ablation. Pain relief from
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A

B

C

D

Fig. 4. 82-year-old woman with thigh sarcoma metastatic to the posterior L5 vertebral body. Axial bone windowed CT image (A)
with destructive right posterior L5 lesion (white arrow). Lateral (B) and frontal (C) fluoroscopic images during RFA with the
articulated bipolar device within the posterior lesion placed from a right pedicular approach. Axial (D) post-ablation T1 image
demonstrating overlapping ablation zones (white arrows).

cementoplasty has been reported in the literature to
range from 47% to 87% (32). Prior destruction of tumor with RFA has been linked to a more complete fill
with cement providing additional structural support
(12,33,34). A synergistic response between RFA and
cementoplasty has been reported which can provide
pain relief for an average of 7.3 months (35). The combination of cement augmentation following RFA using

www.painphysicianjournal.com

the STAR tumor ablation system was shown to be both
safe and efficient, allowing the patient to undergo
both treatments using the same working cannula and
decreasing the total sedation and procedural time.
There are several limitations to this retrospective
study. While a prospective study design is preferred,
observational studies are the mainstay for initial procedure reports.
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A

B
Fig. 5. 32-year-old woman with metastatic colon cancer
who has back pain centered at metastatic lesions at T8
and T9 previously treated with radiation therapy.
Sagittal T1 weighted inversion recovery MRI image
(A) with anterior metastatic lesion and pathologic
superior endplate fracture of T8 (white arrow).
Metastatic lesion at T9 is not shown. Lateral
fluoroscopic image (B) during vertebral augmentation
of T8 and T9 with visualized pathologic superior
endplate fracture of T8 (white arrow). Sagittal T1
weighted fat suppressed post contrast MRI image (C)
5 months following vertebral augmentation (white
asterisks) without ablation demonstrating new tumor in
the posterior vertebral bodies with central canal extension
at both T8 and T9 (arrows).

C
The breadth of demographic and treatment data
provided by each treatment center varied widely. Detailed data was obtained in the center which treated
the most patients, but not available from the other
4 centers. While the calculated P-values were statistically significant within the 70 lesions treated by this
one center, providing some support for the ability to
generalize the data from this center, a more cohesive
data set from all centers would have been beneficial.
Data collected from each center was heterogeneous.
Six month postoperative VAS scores were only recorded
at one institution, and could only be obtained in 9 patients due to patient death from metastatic disease or
loss to follow-up. By the same regard, VAS scores were
not obtained at every time point for each patient even
within the same institution.
Additionally, the patient population was very heterogeneous with a variety of primary tumor types and degree
of metastatic involvement. Due to the innate severity of
metastatic disease, many patients had only a few months
to live allowing for a wide range of follow-up data.
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The majority of the ablations were followed by
cement augmentation which confounds the postprocedural pain evaluation as to the contributing
factor of pain reduction. Most lesions had pathologic
fractures or were at risk of fracture and vertebral
augmentation was used for stabilization. It has well
been accepted that vertebral augmentation is a therapeutic option for pain palliation and stabilization of
pathologic fractures of the spine (36). However, with
vertebral augmentation alone and especially in those
who have failed or exhausted radiation therapy,
there can be progression of disease in the posterior vertebral body where cement is typically absent
with subsequent posterior wall destruction and canal extension (Fig. 5). In this series of patients with
posterior wall involvement and posterior RFA, there
were cases where posterior wall extension was halted
following RFA while spinal tumors in other vertebra
progressed during continued systemic therapy (Fig.
6). In the cases (n = 2) in which tumor progression was
observed, the STAR procedure permitted additional
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Fig. 6. 55-year-old woman who has metastatic renal cell cancer with back pain centered at metastatic lesions and pathologic
fractures of L2 and L3 treated previously with radiation therapy.
Sagittal T1 weighted post contrast MRI image (A) demonstrating large enhancing lesions at L2 and L3 and smaller enhancing
lesions at T11 and T12 prior to ablation. L1 and L5 are labeled for counting purposes. Sagittal T1 weighted post contrast MRI
image (B) 6 months post L2 and L3 ablation with cement augmentation demonstrating a lack of tumor progression within
the treated levels, including posteriorly where no cement was administered (white asterisks), while the adjacent T11 and T12
non-ablated lesions (white arrows) markedly increased in size while on systemic therapy. Axial T2 weighted MRI image (C)
demonstrates progression of the T11 tumor into the spinal canal.
www.painphysicianjournal.com
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treatment without cumulative toxicity associated
with other adjunctive therapies.

Conclusion
In conclusion, this retrospective study demonstrates both the safety and efficacy of the STAR Tumor
Ablation System for treatment of painful metastatic
osseous lesions. There were reproducible, predictable
ablation zones with real time monitoring of the peripheral edge of the ablation zone with the use of the
2 built-in thermocouples. Post-ablation MRI and PET/
CT confirmed size of ablation with necrosis of the tar-

geted tissue. The ablation zone was consistent in size
with that measured by the thermocouples and similar
in morphology to that extrapolated from thermal distribution curves. The articulating electrode provided
easy access to posterior vertebral body lesions that
were previously difficult to access with other ablation
devices. Follow-up imaging demonstrated no further
growth or canal extension of treated tumor. In many
cases, this technique allowed for access and treatment
of individual lesions not accessible by conventional RFA
devices and/or controlled by systemic chemotherapy or
radiation therapy.
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